A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Phase 3
586
about 3.6 years
60–85
28 sites in CA, CO, DC +14
What this study is about
Researchers are testing whether KarXT plus KarX-EC, a treatment, improves cognitive function in people with Alzheimer's disease. The trial will last 1320 days and involve approximately 586 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take KarX-EC
- 3.Take KarXT
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11)
Secondary: Change from baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL), Change from baseline in neuro psychiatric inventory (NPI) total score, Number of participants with AEs leading to death, Number of participants with AEs leading to study discontinuation, Number of participants with AEs leading to study intervention discontinuation, Number of participants with adverse event of special interest (AESIs), Number of participants with adverse events (AEs), Number of participants with serious adverse events (SAEs)
Neurology